EMGNX
Price
$26.15
Change
-$0.26 (-0.98%)
Updated
Dec 20 closing price
RNWFX
Price
$77.72
Change
+$0.12 (+0.15%)
Updated
Dec 20 closing price
Ad is loading...

EMGNX vs RNWFX

Header iconEMGNX vs RNWFX Comparison
Open Charts EMGNX vs RNWFXBanner chart's image
Allspring Emerging Markets Equity Inst
Price$26.15
Change-$0.26 (-0.98%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$77.72
Change+$0.12 (+0.15%)
VolumeN/A
CapitalizationN/A
EMGNX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EMGNX vs. RNWFX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EMGNX is a Hold and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 62.2B vs. EMGNX (3.72B). RNWFX pays higher dividends than EMGNX: RNWFX (1.51) vs EMGNX (1.24). EMGNX was incepted earlier than RNWFX: EMGNX (14 years) vs RNWFX (23 years). RNWFX is a more actively managed with annual turnover of: 32.00 vs. EMGNX (4.00). RNWFX has a lower initial minimum investment than EMGNX: RNWFX (250) vs EMGNX (1000000). EMGNX annual gain was more profitable for investors over the last year : 6.55 vs. RNWFX (5.86). RNWFX return over 5 years is better than : 14.39 vs. EMGNX (-3.06).
EMGNXRNWFXEMGNX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence14 years23 years-
Gain YTD4.7804.549105%
Front LoadN/AN/A-
Min. Initial Investment1000000250400,000%
Min. Initial Investment IRAN/AN/A-
Net Assets3.72B62.2B6%
Annual Yield % from dividends1.241.5182%
Returns for 1 year6.555.86112%
Returns for 3 years-8.16-5.10160%
Returns for 5 years-3.0614.39-21%
Returns for 10 years36.3742.6785%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTRS12.520.39
+3.22%
Viatris
TEO11.890.14
+1.19%
Telecom Argentina SA
DX12.570.14
+1.13%
Dynex Capital
INTT7.680.04
+0.52%
inTEST Corp
VIRX0.21N/A
-1.87%
Viracta Therapeutics